Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Director · President and CEO | October 01, 2026 | October 05, 2026 |
| VERACYTE, INC.VCYT · Entity 2018 | Chief Commercial Officer | December 02, 2020 | December 04, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 644,937 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Tax withholding · Disposed 8,511 · Balance 644,937 F1: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
VERACYTE, INC.
Report date December 02, 2020 · Filed December 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,844 |
Reported balance
After 2020-12-02 transaction · row 1
1 source rowRow 1 · 2020-12-02 · Tax withholding · Disposed 465 · Balance 73,844 F1: The reporting person is reporting the withholding of 217 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 437 and 500 Restricted Stock Units, respectively, granted on March 2, 2018 and February 28, 2019, respectively and does not represent a sale by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is reporting the withholding of 217 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 437 and 500 Restricted Stock Units, respectively, granted on March 2, 2018 and February 28, 2019, respectively and does not represent a sale by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 22:47 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 8,511 | $66.23 | $563,683.53 |
DisclosureSEC source: 0001781127-26-000013 · form4-10052026_101043.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 644,937 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:23 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 118,000 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001781127-26-000012 · form4-07172026_080725.xml · derivative · entry 4 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 512,706 Underlying: Common Stock · 118,000 shares Expires 2034-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on April 15, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:23 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 68,000 | $39.01 | $2,652,931.60 |
DisclosureSEC source: 0001781127-26-000012 · form4-07172026_080725.xml · nonDerivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 653,448 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:23 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 50,000 | $36.11 | $1,805,705.00 |
DisclosureSEC source: 0001781127-26-000012 · form4-07172026_080725.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 721,448 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.56 to $36.51 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:23 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 118,000 | $8.20 | $967,600.00 |
DisclosureSEC source: 0001781127-26-000012 · form4-07172026_080725.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 771,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:05 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 8,511 | $29.25 | $248,946.75 |
DisclosureSEC source: 0001781127-26-000011 · form4-07062026_040701.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 653,448 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 39,900 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · derivative · entry 12 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 630,706 Underlying: Common Stock · 39,900 shares Expires 2034-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on April 15, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 39,900 | $29.24 | $1,166,835.60 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · nonDerivative · entry 7 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 661,959 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.58 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 39,900 | $8.20 | $327,180.00 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · nonDerivative · entry 6 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 701,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · derivative · entry 11 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 670,606 Underlying: Common Stock · 100 shares Expires 2034-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on April 15, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 100 | $29.00 | $2,900.00 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · nonDerivative · entry 5 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 661,959 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 100 | $8.20 | $820.00 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · nonDerivative · entry 4 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 662,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:05 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 17,683 | $24.03 | $424,876.51 |
DisclosureSEC source: 0001781127-26-000009 · form4-06172026_040601.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 631,959 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.0309 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,676 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · derivative · entry 10 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 670,706 Underlying: Common Stock · 15,676 shares Expires 2034-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on April 15, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| June 15, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 15,676 | $8.20 | $128,543.20 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · nonDerivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 661,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:06 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 21,998 | $24.02 | $528,442.56 |
DisclosureSEC source: 0001781127-26-000008 · form4-06152026_090627.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 649,642 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,618 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · derivative · entry 9 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 686,382 Underlying: Common Stock · 13,618 shares Expires 2034-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on April 15, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| June 11, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 13,618 | $8.20 | $111,667.60 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 646,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:05 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 4,835 | $24.00 | $116,044.84 |
DisclosureSEC source: 0001781127-26-000007 · form4-06082026_040601.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 671,640 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 706 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · derivative · entry 8 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 706 shares Expires 2034-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on April 15, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| June 04, 2026 Filed Jun 30, 2026 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 706 | $8.20 | $5,789.20 |
DisclosureSEC source: 0001781127-26-000010 · form4-06302026_090602.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 632,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 20:53 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 10,282 | $21.12 | $217,155.84 |
DisclosureSEC source: 0001781127-26-000006 · form4-04202026_080450.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 676,475 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 20:05 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 62,049 | $17.57 | $1,090,200.93 |
DisclosureSEC source: 0001781127-26-000005 · form4-04162026_040401.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 686,757 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:05 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 35,037 | $17.87 | $626,111.19 |
DisclosureSEC source: 0001781127-26-000004 · form4-04032026_080457.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 748,806 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:21 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 13,694 | $20.42 | $279,631.48 |
DisclosureSEC source: 0001781127-26-000003 · form4-02042026_090240.xml · nonDerivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 783,843 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of PRSUs. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:21 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 37,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001781127-26-000003 · form4-02042026_090240.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 797,537 F2 · shares: The reported securities were subject to a performance restricted stock unit ("PRSU") award that was initially granted on February 1, 2025, and were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation and Human Capital Committee of the Issuer's Board of Directors on February 2, 2026. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:21 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 162,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001781127-26-000003 · form4-02042026_090240.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 759,905 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), of which one-third will vest on April 6, 2027 and the remaining two-thirds will vest in equal quarterly installments thereafter on the last day of each of the subsequent eight quarters, rounded down to the nearest whole share until the last such installment, such that one-hundred percent of the RSUs will be vested on the third anniversary of April 6, 2027, subject to the Reporting Person's continuous employment on each applicable vesting date. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 22:58 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 19,280 | $21.16 | $408,022.64 |
DisclosureSEC source: 0001781127-26-000002 · form4-01232026_100106.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 597,405 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.43 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:58 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 200 | $21.00 | $4,200.00 |
DisclosureSEC source: 0001781127-26-000002 · form4-01232026_100106.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 616,685 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 22:30 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 10,156 | $21.05 | $213,804.11 |
DisclosureSEC source: 0001781127-26-000001 · form4-01202026_100130.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 616,885 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.18 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 20:35 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 61,469 | $19.16 | $1,177,746.04 |
DisclosureSEC source: 0001781127-25-000004 · wk-form4_1744922094.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,041 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 20:30 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 200,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001781127-25-000002 · wk-form4_1742934645.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 688,510 F1 · shares: The reported securities are represented by restricted stock units, of which one-third will vest on April 1, 2026 and the remaining two-thirds will vest in equal quarterly installments thereafter on the last day of each of the subsequent eight quarters, rounded down to the nearest whole share until the last such installment, such that one-hundred percent of the restricted stock units will be vested on the third anniversary of April 1, 2026, subject to the Reporting Person's continuous employment on each applicable vesting date. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 22:57 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 465 | $55.08 | $25,612.20 |
DisclosureSEC source: 0001437749-20-024886 · rdgdoc.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,844 F1 · kind: The reporting person is reporting the withholding of 217 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 437 and 500 Restricted Stock Units, respectively, granted on March 2, 2018 and February 28, 2019, respectively and does not represent a sale by the reporting person. Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 21:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 21,250 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001437749-20-023244 · rdgdoc.xml · derivative · entry 4 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,750 Underlying: Common Stock · 21,250 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. F4 · derivative.exercise_date: The option became exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 21:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,200 | $44.19 | $53,030.52 |
DisclosureSEC source: 0001437749-20-023244 · rdgdoc.xml · nonDerivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,309 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $44.03 to $44.41. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 21:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 20,050 | $43.40 | $870,075.77 |
DisclosureSEC source: 0001437749-20-023244 · rdgdoc.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,509 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $43.00 to $44.00. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 21:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 21,250 | $20.21 | $429,462.50 |
DisclosureSEC source: 0001437749-20-023244 · rdgdoc.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,281 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001437749-20-023003 · rdgdoc.xml · derivative · entry 7 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,782 Underlying: Common Stock · 3,281 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. F6 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001437749-20-023003 · rdgdoc.xml · derivative · entry 6 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,292 Underlying: Common Stock · 3,125 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. F5 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 133 | $42.08 | $5,596.65 |
DisclosureSEC source: 0001437749-20-023003 · rdgdoc.xml · nonDerivative · entry 5 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,309 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $42.05 to $42.13. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,660 | $41.56 | $110,548.00 |
DisclosureSEC source: 0001437749-20-023003 · rdgdoc.xml · nonDerivative · entry 4 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,442 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $41.01 to $42.01. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,613 | $40.00 | $144,506.27 |
DisclosureSEC source: 0001437749-20-023003 · rdgdoc.xml · nonDerivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,102 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $39.95 to $40.78. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,281 | $5.98 | $19,620.38 |
DisclosureSEC source: 0001437749-20-023003 · rdgdoc.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,125 | $9.05 | $28,281.25 |
DisclosureSEC source: 0001437749-20-023003 · rdgdoc.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 21:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 325 | $34.16 | $11,102.00 |
DisclosureSEC source: 0001437749-20-019355 · rdgdoc.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,309 F1 · kind: The reporting person is reporting the withholding of 152 and 173 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 438 and 500 Restricted Stock Units, respectively, granted on March 2, 2018 and February 28, 2019, respectively and does not represent a sale by the reporting person. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 21:08 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 9,844 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001437749-20-019131 · rdgdoc.xml · derivative · entry 14 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,063 Underlying: Common Stock · 9,844 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2020. F6 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 21:08 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 9,375 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001437749-20-019131 · rdgdoc.xml · derivative · entry 13 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,417 Underlying: Common Stock · 9,375 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2020. F5 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 21:08 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 19,336 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001437749-20-019131 · rdgdoc.xml · derivative · entry 12 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 19,336 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2020. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 21:08 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 8,835 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001437749-20-019131 · rdgdoc.xml · derivative · entry 11 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 8,835 shares Expires 2025-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2020. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 21:08 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001437749-20-019131 · rdgdoc.xml · derivative · entry 10 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2020. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.